Feasibility of cell-free circulating tumor DNA testing for lung cancer

Mariacarmela Santarpia, Niki Karachaliou, Maria González-Cao, Giuseppe Altavilla, Elisa Giovannetti, Rafael Rosell

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing, may offer a limited evaluation because of tumor heterogeneity and can be difficult to obtain. Cell-free circulating tumor DNA has been widely investigated as a potential surrogate for tissue biopsy for noninvasive assessment of tumor-related genomic alterations. New techniques have improved EGFR mutations detection in ctDNA, thus supporting the use of this liquid biopsy for predicting response to EGFR tyrosine kinase inhibitors (TKIs) and monitoring the emergence of resistance. The serial evaluation of ctDNA during treatment is feasible and can be used to track tumor changes in real time and for a wide range of clinically useful applications.

Original languageEnglish
Pages (from-to)417-430
Number of pages14
JournalBiomarkers in Medicine
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Circulating Neoplastic Cells
Tumors
Lung Neoplasms
Biopsy
DNA
Testing
Neoplasms
Tissue
Mutation
Protein-Tyrosine Kinases
Monitoring
Liquids

Keywords

  • circulating cell-free DNA (cfDNA)
  • EGFR mutations
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

Santarpia, M., Karachaliou, N., González-Cao, M., Altavilla, G., Giovannetti, E., & Rosell, R. (2016). Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomarkers in Medicine, 10(4), 417-430. https://doi.org/10.2217/bmm.16.6

Feasibility of cell-free circulating tumor DNA testing for lung cancer. / Santarpia, Mariacarmela; Karachaliou, Niki; González-Cao, Maria; Altavilla, Giuseppe; Giovannetti, Elisa; Rosell, Rafael.

In: Biomarkers in Medicine, Vol. 10, No. 4, 01.04.2016, p. 417-430.

Research output: Contribution to journalArticle

Santarpia, M, Karachaliou, N, González-Cao, M, Altavilla, G, Giovannetti, E & Rosell, R 2016, 'Feasibility of cell-free circulating tumor DNA testing for lung cancer', Biomarkers in Medicine, vol. 10, no. 4, pp. 417-430. https://doi.org/10.2217/bmm.16.6
Santarpia M, Karachaliou N, González-Cao M, Altavilla G, Giovannetti E, Rosell R. Feasibility of cell-free circulating tumor DNA testing for lung cancer. Biomarkers in Medicine. 2016 Apr 1;10(4):417-430. https://doi.org/10.2217/bmm.16.6
Santarpia, Mariacarmela ; Karachaliou, Niki ; González-Cao, Maria ; Altavilla, Giuseppe ; Giovannetti, Elisa ; Rosell, Rafael. / Feasibility of cell-free circulating tumor DNA testing for lung cancer. In: Biomarkers in Medicine. 2016 ; Vol. 10, No. 4. pp. 417-430.
@article{ae2c2d6eed1a460ea128a47d083ae7ed,
title = "Feasibility of cell-free circulating tumor DNA testing for lung cancer",
abstract = "Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing, may offer a limited evaluation because of tumor heterogeneity and can be difficult to obtain. Cell-free circulating tumor DNA has been widely investigated as a potential surrogate for tissue biopsy for noninvasive assessment of tumor-related genomic alterations. New techniques have improved EGFR mutations detection in ctDNA, thus supporting the use of this liquid biopsy for predicting response to EGFR tyrosine kinase inhibitors (TKIs) and monitoring the emergence of resistance. The serial evaluation of ctDNA during treatment is feasible and can be used to track tumor changes in real time and for a wide range of clinically useful applications.",
keywords = "circulating cell-free DNA (cfDNA), EGFR mutations, non-small-cell lung cancer",
author = "Mariacarmela Santarpia and Niki Karachaliou and Maria Gonz{\'a}lez-Cao and Giuseppe Altavilla and Elisa Giovannetti and Rafael Rosell",
year = "2016",
month = "4",
day = "1",
doi = "10.2217/bmm.16.6",
language = "English",
volume = "10",
pages = "417--430",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Feasibility of cell-free circulating tumor DNA testing for lung cancer

AU - Santarpia, Mariacarmela

AU - Karachaliou, Niki

AU - González-Cao, Maria

AU - Altavilla, Giuseppe

AU - Giovannetti, Elisa

AU - Rosell, Rafael

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing, may offer a limited evaluation because of tumor heterogeneity and can be difficult to obtain. Cell-free circulating tumor DNA has been widely investigated as a potential surrogate for tissue biopsy for noninvasive assessment of tumor-related genomic alterations. New techniques have improved EGFR mutations detection in ctDNA, thus supporting the use of this liquid biopsy for predicting response to EGFR tyrosine kinase inhibitors (TKIs) and monitoring the emergence of resistance. The serial evaluation of ctDNA during treatment is feasible and can be used to track tumor changes in real time and for a wide range of clinically useful applications.

AB - Tumor tissue genotyping is used routinely for lung cancer to identify specific targetable oncogenic alterations, including EGFR mutations and ALK rearrangements. However, tumor tissue from a single biopsy is often insufficient for molecular testing, may offer a limited evaluation because of tumor heterogeneity and can be difficult to obtain. Cell-free circulating tumor DNA has been widely investigated as a potential surrogate for tissue biopsy for noninvasive assessment of tumor-related genomic alterations. New techniques have improved EGFR mutations detection in ctDNA, thus supporting the use of this liquid biopsy for predicting response to EGFR tyrosine kinase inhibitors (TKIs) and monitoring the emergence of resistance. The serial evaluation of ctDNA during treatment is feasible and can be used to track tumor changes in real time and for a wide range of clinically useful applications.

KW - circulating cell-free DNA (cfDNA)

KW - EGFR mutations

KW - non-small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84962168925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962168925&partnerID=8YFLogxK

U2 - 10.2217/bmm.16.6

DO - 10.2217/bmm.16.6

M3 - Article

AN - SCOPUS:84962168925

VL - 10

SP - 417

EP - 430

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 4

ER -